Mipasetamab Biosimilar – Anti-AXL mAb – Research Grade

Description of Mipasetamab Biosimilar - Anti-AXL mAb - Research Grade

Introduction

Mipasetamab Biosimilar, also known as Anti-AXL mAb, is a research grade monoclonal antibody that targets the AXL receptor tyrosine kinase. AXL is a cell surface protein that plays a crucial role in cell growth, survival, and migration. Dysregulation of AXL has been linked to various diseases, making it an attractive therapeutic target. In this article, we will discuss the structure, activity, and potential applications of Mipasetamab Biosimilar as an anti-AXL monoclonal antibody.

Structure of Mipasetamab Biosimilar

Mipasetamab Biosimilar is a fully human monoclonal antibody that is produced using recombinant DNA technology. It is composed of two identical heavy chains and two identical light chains, each with a molecular weight of approximately 150 kDa. The heavy chains consist of four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chains contain one constant domain (CL) and one variable domain (VL). The variable domains of both heavy and light chains are responsible for binding to the AXL receptor.

Activity of Mipasetamab Biosimilar

Mipasetamab Biosimilar binds to the extracellular domain of AXL with high affinity, thereby blocking its interaction with its ligand, Gas6. This inhibits the activation of downstream signaling pathways, such as PI3K/AKT and MAPK, which are involved in cell proliferation, survival, and migration. Additionally, Mipasetamab Biosimilar induces internalization and degradation of AXL, leading to further reduction in AXL signaling. This dual mechanism of action makes Mipasetamab Biosimilar a potent inhibitor of AXL activity.

Potential Applications of Mipasetamab Biosimilar

The dysregulation of AXL has been implicated in various diseases, including cancer, fibrosis, and autoimmune disorders. Therefore, Mipasetamab Biosimilar has the potential to be used in the treatment of these diseases. In cancer, AXL has been shown to promote tumor growth, metastasis, and resistance to chemotherapy and targeted therapies. By inhibiting AXL activity, Mipasetamab Biosimilar can potentially slow down tumor growth and sensitize cancer cells to existing therapies. Clinical trials are currently underway to evaluate the efficacy of Mipasetamab Biosimilar in various types of cancer, including non-small cell lung cancer, breast cancer, and acute myeloid leukemia.

In addition to cancer, AXL has also been implicated in fibrosis, a condition characterized by excessive scarring and tissue damage. AXL promotes the activation of fibroblasts, leading to the deposition of collagen and other extracellular matrix proteins. This results in tissue fibrosis and organ dysfunction. Mipasetamab Biosimilar has shown promising results in preclinical studies as a potential treatment for fibrosis by inhibiting AXL-mediated fibroblast activation. Clinical trials are currently ongoing to evaluate its efficacy in patients with idiopathic pulmonary fibrosis and systemic sclerosis.

Furthermore, AXL has been shown to play a role in autoimmune disorders, such as rheumatoid arthritis and systemic lupus erythematosus. In these conditions, AXL promotes the production of pro-inflammatory cytokines and the activation of immune cells, contributing to disease progression. Mipasetamab Biosimilar has shown potential as a therapeutic agent in preclinical studies by inhibiting AXL-mediated inflammation. Clinical trials are currently underway to evaluate its efficacy in patients with rheumatoid arthritis and lupus.

Conclusion

In summary, Mipasetamab Biosimilar is a research grade monoclonal antibody that specifically targets the AXL receptor. Its unique structure and dual mechanism of action make it a potent inhibitor of AXL activity. Clinical trials are currently underway to evaluate its efficacy in various diseases, including cancer, fibrosis, and autoimmune disorders. If successful, Mipasetamab Biosimilar has the potential to become a valuable therapeutic option for patients with these conditions.